Wabash National posts narrower Q2 loss on strong shipments
Reuters2026/07/29 11:03
Overview
U.S. trailer maker's Q2 revenue fell 9% yr/yr, slightly above prior-year period
Adjusted EPS loss for Q2 was $(0.53), within company guidance range
Company backlog rose 14% from Q1, outperforming seasonal trends
Outlook
Wabash guides Q3-2026 revenue to $440 mln-$460 mln, midpoint $450 mln
Company expects Q3-2026 non-GAAP EPS of $(0.50) to $(0.40)
Company says freight market recovery and improving carrier economics expected to support results
Result Drivers
DRY VAN SHIPMENTS - Co said quarterly revenue reflected strong shipments in core Dry Van market
PARTS SERVICES GROWTH - Parts Services segment generated positive revenue growth yr/yr
IMPROVING MARKET FUNDAMENTALS - Co cited healthier supply-side forces, safety-focused federal enforcement, and improving carrier economics assupporting better market conditions, per CEO Brent Yeagy
Company press release: ID:nGNX5rM1S6
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Revenue |
Slight Beat* |
$417.20 mln |
$415.70 mln (1 Analyst) |
Q2 Adjusted Loss Per Share |
Beat |
$0.53 |
$0.56 (2 Analysts) |
Q2 Loss Per Share |
|
$0.56 |
|
Q2 Operating Income |
|
-$25 mln |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Wabash National Corp is $22.50, about 69% above its July 28 closing price of $13.31
Reuters Recommended Reads
July 28 - Landstar Q2 revenue beats estimates as freight transportation market "rapidly" improves
July 28 - Werner Q2 revenue rises on TTS growth, FirstFleet acquisition
July 29 - Luxembourg's Logwin H1 revenue rises on higher freight rates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street -- WSJ
NASDAQ TRADE HALT CONTINUES <EFTY.O> REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES <UCFIW.O> REASON NOT AVAILABLE AT 03:28 AM